Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GSK2118436 Clear all
Completed Phase 2 Interventional Results available

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

NCT01619774
View directory record Official record
Conditions
Melanoma
Interventions
GSK2118436, GSK1120212
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 19, 2026, 10:28 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

NCT01738451
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436 75 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 19, 2026, 10:28 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052
View directory record Official record
Conditions
Differentiated Thyroid Cancer (DTC)
Interventions
Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Terminated Phase 2 Interventional Results available

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

NCT04527549
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
199
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Terminated Early Phase 1 Interventional

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

NCT02382549
View directory record Official record
Conditions
Melanoma
Interventions
BRAF inhibitor, 6MHP, MEK inhibitor
Drug · Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 19, 2026, 10:28 AM EDT
Completed No phase listed Observational

Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

NCT05806268
View directory record Official record
Conditions
BRAF v600 Mutated Metastatic Melanoma
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 19, 2026, 10:28 AM EDT
Terminated Phase 1 Interventional

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

NCT03878524
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
Drug · Biological · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 19, 2026, 10:28 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457
View directory record Official record
Conditions
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
Interventions
Dabrafenib, Trametinib, Hydroxychloroquine
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 30 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

NCT06712875
View directory record Official record
Conditions
Low Grade Glioma, High Grade Glioma
Interventions
Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 26 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

NCT02124772
View directory record Official record
Conditions
Cancer
Interventions
Trametinib, Dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 19, 2026, 10:28 AM EDT
Terminated Phase 2 Interventional Results available

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

NCT01978236
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib 150 mg, Trametinib 2.0 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 19, 2026, 10:28 AM EDT
Completed No phase listed Observational

Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma

NCT06557291
View directory record Official record
Conditions
BRAF V600 Mutated-Stage III/IV Melanoma
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 19, 2026, 10:28 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

NCT01682213
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 19, 2026, 10:28 AM EDT
Recruiting Phase 2 Interventional

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

NCT07110246
View directory record Official record
Conditions
BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Interventions
Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Months to 25 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Recruiting Phase 3 Interventional

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

NCT06475989
View directory record Official record
Conditions
Refractory Differentiated Thyroid Gland Carcinoma
Interventions
Biospecimen Collection, Cabozantinib, Computed Tomography, Dabrafenib, Magnetic Resonance Imaging, Questionnaire Administration, Trametinib
Procedure · Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
307
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 222 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Not listed Phase 1 Interventional

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

NCT03088176
View directory record Official record
Conditions
Melanoma, BRAF Gene Mutation
Interventions
Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib, Trametinib
Drug
Lead sponsor
West Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 19, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Results available

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

NCT01682083
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Placebos
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

NCT02034110
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 19, 2026, 10:28 AM EDT
Not listed Phase 2 Interventional

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

NCT03668431
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Dabrafenib, Trametinib, PDR001
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 19, 2026, 10:28 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

NCT04557956
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions
Biopsy Procedure, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tazemetostat Hydrobromide, Trametinib Dimethyl Sulfoxide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Aventura, Florida • Coral Gables, Florida • Deerfield Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Recruiting Phase 1 Interventional

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

NCT04903119
View directory record Official record
Conditions
Metastatic Melanoma, BRAF Gene Mutation
Interventions
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib, Encorafenib, Binimetinib
Drug
Lead sponsor
Rina Plattner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
4
States / cities
Iowa City, Iowa • Lexington, Kentucky • Easton, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Active, not recruiting Phase 2 Interventional

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT04544111
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Hurthle Cell Thyroid Neoplasia
Interventions
Trametinib, Dabrafenib, PDR001
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 19, 2026, 10:28 AM EDT
Terminated Phase 1 Interventional Results available

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

NCT03332589
View directory record Official record
Conditions
Malignant Melanoma, Brain Metastases
Interventions
E6201, E6201 plus dabrafenib
Drug
Lead sponsor
Spirita Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 19, 2026, 10:28 AM EDT
Completed Phase 1 Interventional

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

NCT02082665
View directory record Official record
Conditions
Cancer
Interventions
Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 19, 2026, 10:28 AM EDT